The Challenges We Address

Modern drug discovery is accelerating faster than ever — driven by AI, platform biology, and new therapeutic modalities.
But for many of these breakthroughs, manufacturing has become the bottleneck.

When Discovery Outpaces Manufacturing

Scientific innovation is no longer the limiting factor.
The challenge is translating novel therapies into real, repeatable manufacturing processes.

Many of today’s therapies are scientifically viable but physically hard to manufacture, because the tools used to produce them were designed for a previous generation of drugs.

As modalities become more fragile, more concentrated, and more complex, legacy bioprocessing technology breaks down.

Where Legacy Technology Falls Short

Across the industry, teams increasingly face:

• Fragile and advanced modalities
  Therapies such as mRNA, LNPs, viral vectors, and cell & gene therapies that are highly sensitive to mechanical stress.

• Hidden yield and potency loss
  Product damage driven by cavitation, pressure transients, and unstable flow — often misattributed to “shear.”

• The PD → GMP manufacturability gap
  Processes that work at small scale but fail when mechanical conditions change during scale-up.

• Tools that can’t keep up
  Hardware optimised for legacy processes, not the next generation of medicines.

How Alphinity Is Different

We don’t make drugs.
We enable scientists and manufacturers to make drugs that legacy technology cannot support.

Alphinity develops next-generation precision flow control components and engineer-to-order bioprocessing systems designed around flow behaviour, pressure stability, and physical process continuity.

Instead of forcing processes to adapt to equipment, we design systems that adapt to the process — from early development through GMP manufacturing.

Our Role in the Industry

Alphinity sits at the critical transition point where therapies move from discovery into real manufacturing.

We provide the tools and systems that allow innovators to:

• Protect fragile products

• Maintain quality and potency

• Preserve physical process conditions during scale-up

• Accelerate time from concept to clinic

This is how we help enable the next wave of medicines.